NTRB
$3.91
Nutriband Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with a...
Recent News
The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Nutriband says ‘committed’ to shareholder value as ‘number one focus’
Nutriband (NTRB) announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The letter read, in part, “As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the begin
MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +70.37% and -15.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of +26.44% and -27.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?